THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS

In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment right until sickness progression or even the members are unable to tolerate the study drugs.- Participant consumed grapefruit or grapefruit products within three days prior to the very f